Amneal Pharmaceuticals, Inc. (FRA:2DT)
Germany · Delayed Price · Currency is EUR 12.10
-0.50 (-3.97%)
At close: Feb 20, 2026
Amneal Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Revenue | 2,935 | 2,794 | 2,394 | 2,212 | 2,094 | 1,993 |
Revenue Growth (YoY) | 9.50% | 16.73% | 8.20% | 5.67% | 5.08% | 22.51% |
Cost of Revenue | 1,841 | 1,778 | 1,530 | 1,421 | 1,310 | 1,340 |
Gross Profit | 1,094 | 1,016 | 863.87 | 791.46 | 783.95 | 652.32 |
Selling, General & Admin | 509.06 | 476.44 | 429.68 | 399.7 | 365.5 | 326.73 |
Research & Development | 205.62 | 190.71 | 163.95 | 195.69 | 201.85 | 179.93 |
Other Operating Expenses | -4.31 | - | -1.14 | -3.96 | - | - |
Operating Expenses | 710.37 | 667.15 | 592.49 | 591.43 | 567.35 | 506.66 |
Operating Income | 383.33 | 348.36 | 271.38 | 200.03 | 216.6 | 145.66 |
Interest Expense | -246.52 | -258.6 | -210.63 | -158.38 | -136.33 | -146 |
Currency Exchange Gain (Loss) | 1.41 | -6.85 | 1.67 | -12.36 | -0.36 | 16.35 |
Other Non Operating Income (Expenses) | -20.25 | -42.66 | 5.12 | 17.83 | 15.33 | 2.59 |
EBT Excluding Unusual Items | 117.98 | 40.26 | 67.54 | 47.13 | 95.25 | 18.6 |
Merger & Restructuring Charges | -2.23 | -2.36 | -1.75 | -2.13 | -9.91 | -11.39 |
Gain (Loss) on Sale of Assets | 7.52 | 3.76 | - | - | - | 0.12 |
Asset Writedown | -22.78 | -0.92 | -36.13 | -11.11 | -22.69 | -34.58 |
Legal Settlements | -1.39 | -96.69 | -1.82 | -269.93 | -25 | -5.86 |
Other Unusual Items | -30.44 | 0.93 | -37.31 | -1.02 | -10.57 | - |
Pretax Income | 68.66 | -55.01 | -40.27 | -248.13 | 31.37 | -35.78 |
Income Tax Expense | 11.04 | 18.86 | 8.45 | 6.66 | 11.2 | -104.36 |
Earnings From Continuing Operations | 57.62 | -73.88 | -48.72 | -254.79 | 20.17 | 68.58 |
Minority Interest in Earnings | -51.72 | -43.01 | -35.27 | 124.8 | -9.55 | 22.48 |
Net Income | 5.9 | -116.89 | -83.99 | -129.99 | 10.62 | 91.06 |
Net Income to Common | 5.9 | -116.89 | -83.99 | -129.99 | 10.62 | 91.06 |
Net Income Growth | - | - | - | - | -88.33% | - |
Shares Outstanding (Basic) | 312 | 309 | 176 | 151 | 149 | 147 |
Shares Outstanding (Diluted) | 320 | 309 | 176 | 151 | 152 | 149 |
Shares Change (YoY) | 9.44% | 75.42% | 16.69% | -0.58% | 1.95% | 12.72% |
EPS (Basic) | 0.02 | -0.38 | -0.48 | -0.86 | 0.07 | 0.62 |
EPS (Diluted) | 0.02 | -0.38 | -0.48 | -0.86 | 0.07 | 0.61 |
EPS Growth | - | - | - | - | -88.52% | - |
Free Cash Flow | 249.62 | 234.76 | 298.78 | 16.3 | 190.88 | 317.17 |
Free Cash Flow Per Share | 0.78 | 0.76 | 1.70 | 0.11 | 1.26 | 2.13 |
Gross Margin | 37.27% | 36.35% | 36.09% | 35.77% | 37.44% | 32.74% |
Operating Margin | 13.06% | 12.47% | 11.34% | 9.04% | 10.35% | 7.31% |
Profit Margin | 0.20% | -4.18% | -3.51% | -5.88% | 0.51% | 4.57% |
Free Cash Flow Margin | 8.51% | 8.40% | 12.48% | 0.74% | 9.12% | 15.92% |
EBITDA | 623.81 | 584.55 | 500.78 | 440.21 | 450 | 381.05 |
EBITDA Margin | 21.25% | 20.92% | 20.92% | 19.90% | 21.49% | 19.12% |
D&A For EBITDA | 240.48 | 236.19 | 229.4 | 240.18 | 233.41 | 235.39 |
EBIT | 383.33 | 348.36 | 271.38 | 200.03 | 216.6 | 145.66 |
EBIT Margin | 13.06% | 12.47% | 11.34% | 9.04% | 10.35% | 7.31% |
Effective Tax Rate | 16.08% | - | - | - | 35.70% | - |
Advertising Expenses | - | 34.4 | 12.4 | 16.8 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.